Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD
Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology's (AAO) annual meeting in New Orleans.